Processa (NASDAQ: PCSA) CEO George Ng buys 1,843 shares in open market

Rhea-AI Filing Summary

Processa Pharmaceuticals Chief Executive Officer George K. Ng reported an open-market purchase of 1,843 shares of Common Stock at $2.97 per share. After this transaction, his directly held Common Stock position reported in this filing increased to 3,979 shares.

The filing also lists indirect holdings of 800 shares held by the Ng Cha Family Trust and 3,488 shares held by an account identified as George Ng IRRA FOB George Ng as of the same date.

Insider Trade Summary

Net Buyer: 1,843 shares ($5,474)

Net Buy 3 txns

Insider Ng George K

Role Chief Executive Officer

Bought 1,843 shs ($5K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	1,843	$2.97	$5K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 3,979 shares (Direct, null); Common Stock — 3,488 shares (Indirect, George Ng IRRA FOB George Ng)

Footnotes (1)

Key Figures

Shares purchased: 1,843 shares Purchase price: $2.97 per share Direct holdings after transaction: 3,979 shares +2 more

5 metrics

Shares purchased 1,843 shares Open-market purchase of Common Stock

Purchase price $2.97 per share Price for the 1,843-share open-market buy

Direct holdings after transaction 3,979 shares Common Stock directly held by George K. Ng

Indirect holdings – Ng Cha Family Trust 800 shares Common Stock held indirectly via family trust

Indirect holdings – IRRA account 3,488 shares Common Stock held via George Ng IRRA FOB George Ng

Key Terms

Form 4/A, open-market purchase, Common Stock, indirect ownership, +1 more

5 terms

Form 4/A regulatory

"INSIDER FILING DATA (Form 4/A):"

Form 4/A is an amended filing that corrects or updates an earlier Form 4, the mandatory report that insiders (like company executives, directors, or large shareholders) must file when their ownership stakes change. Think of it as an edited receipt showing who bought or sold stock and when; investors use it to track insider confidence, detect potential conflicts, and spot trading patterns that might signal future company prospects.

open-market purchase financial

""transaction_action": "open-market purchase""

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

Common Stock financial

""security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

indirect ownership financial

""ownership_type": "indirect""

transaction code regulatory

""transaction_code_description": "Purchase in open market or private transaction""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ng George K

(Last) (First) (Middle)

C/O PROCESSA PHARMACEUTICALS, INC.

601 21ST STREET SUITE 300

(Street)

VERO BEACH FLORIDA 32960

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Processa Pharmaceuticals, Inc. [ PCSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
04/17/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/15/2026		P		1,843	A	$2.97	3,979	D
Common Stock								3,488	I	George Ng IRRA FOB George Ng
Common Stock								800	I	Ng Cha Family Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ George Ng, by John J. Wolfel, as Attorney-in-Fact	05/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did PCSA CEO George K. Ng report on this Form 4/A?

George K. Ng reported buying 1,843 shares of Processa Pharmaceuticals Common Stock at $2.97 per share in an open-market transaction. This filing reflects a direct increase in his ownership stake based on the shares and price disclosed for that specific purchase.

How many Processa Pharmaceuticals (PCSA) shares does George K. Ng hold directly after this transaction?

Following the reported purchase, George K. Ng directly holds 3,979 shares of Processa Pharmaceuticals Common Stock. This figure represents his direct ownership position as shown in this Form 4/A after the 1,843-share open-market transaction on the reported date.

What indirect PCSA share holdings related to George K. Ng are disclosed in this Form 4/A?

The filing lists 800 shares of Common Stock held indirectly through the Ng Cha Family Trust and 3,488 shares held through an account identified as George Ng IRRA FOB George Ng, showing additional positions associated with him beyond his directly held shares.

At what price did George K. Ng purchase Processa Pharmaceuticals (PCSA) shares?

The Form 4/A shows that George K. Ng bought 1,843 shares of Processa Pharmaceuticals Common Stock at a price of $2.97 per share in an open-market purchase, indicating the per-share cost he paid for this specific transaction on the reported date.

Does this PCSA Form 4/A show any insider sales by George K. Ng?

No insider sales are reported for George K. Ng in this Form 4/A. The transaction summary reflects one open-market purchase totaling 1,843 shares, with no sell transactions or derivative exercises disclosed in this particular filing.